

Zydus receives final approval from the USFDA for Dutasteride and Tamsulosin Hydrochloride Capsules

Ahmedabad, 25 May, 2018

Zydus Cadila has received the final approval from the USFDA to market Dutasteride and Tamsulosin Hydrochloride Capsules, 0.5 mg/0.4 mg. The drug is used to treat symptoms of Benign Prostatic Hyperplasia (BPH). It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 190 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
